Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome
NCT ID: NCT00440882
Last Updated: 2008-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2004-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to analyse the changes of TGF-b1 and PIIINP during ARDS and to show the relationships between TGF-b1 - PIIINP and the outcomes of ARDS.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin
NCT01988740
sFlt-1:PlGF Ratio in Diagnosing Superimposed Preeclampsia
NCT03441711
First Trimester Placental Assessment in the Screening of Preeclampsia and Intrauterine Growth Restriction
NCT02879942
Fibroblast Growth Factor 23 and Hypertensive Disorder Complicating Pregnancy
NCT03821922
Predicting Placental Pathologies by Ultrasound Imaging
NCT04506970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ARDS criteria from less than 24 hours
* Informed consent
Exclusion Criteria
* Chronic interstitial or fibrosis lung diseases
* Hepatic chronic disease
* Neutropenia £1 G/l
* Corticosteroid (more than 200 mg/day of hydrocortisone or equivalent, less than 2 weeks before inclusion)
* Immunosuppressive therapy within the last 30 days
* Participation in any investigational drug or devices study within 30 days prior study entry
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Assistance Publique Hopitaux De Marseille
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Marie FOREL, MD
Role: PRINCIPAL_INVESTIGATOR
AP-HM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Sainte Marguerite
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004/16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.